GLP-1-based therapies: The dilemma of uncertainty

Gastroenterology

Volumn 141, Issue 1, 2011, Pages 20-23

  Spranger, Joachim ^a   Gundertremy, Ursula ^b   Stammschulte, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Drug Commission of the German Medical Association   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; EPIDERMAL GROWTH FACTOR RECEPTOR; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INCRETIN; LIRAGLUTIDE; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ACINAR CELL; ACUTE PANCREATITIS; BODY COMPOSITION; CANCER RISK; CARDIOVASCULAR RISK; CELL PROLIFERATION; CHRONIC PANCREATITIS; CLINICAL PRACTICE; DISEASE PREDISPOSITION; DRUG EXPOSURE; EDEMA; ENZYME INHIBITION; FAMILY HISTORY; GENE EXPRESSION; GLUCAGON RELEASE; HEART INFARCTION; HISTOPATHOLOGY; HORMONAL THERAPY; HYPERPLASIA; INSULIN RELEASE; METAPLASIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORGAN WEIGHT; PANCREAS CANCER; PANCREAS ISLET BETA CELL; PANCREATIC DUCTAL HYPERPLASIA; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SCIENTIFIC LITERATURE; SMOKING; SRC HOMOLOGY DOMAIN; STROKE; THYROID CANCER; TUMOR GROWTH; WEIGHT REDUCTION;

EID: 79959963949     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.05.019     Document Type: Editorial

References (21)

1. M. Elashoff, A.V. Matveyenko, and B. Gier Pancreatitis, pancreatic and thyroid cancer with glucagon-like peptide-1based therapies Gastroenterology 141 2011 150 156
2. P.L. Brubaker Minireview: update on incretin biology: focus on glucagon-like peptide-1 Endocrinology 151 2010 1984 1989
3. P.S. Denker, and P.E. Dimarco Exenatide (exendin-4)-induced pancreatitis: a case report Diabetes Care 29 2006 471 (Pubitemid 44106551)
4. P. Cure, A. Pileggi, and R. Alejandro Exenatide and rare adverse events N Engl J Med 358 2008 1969 1970 (Pubitemid 351620132)
5. D.D. Dore, G.L. Bloomgren, and M. Wenten A cohort study of acute pancreatitis in relation to exenatide use Diabetes Obes Metab 13 2011 559 566
6. D.D. Dore, J.D. Seeger, and K. Arnold Chan Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide Curr Med Res Opin 25 2009 1019 1027
7. S.S. Engel, D.E. Williams-Herman, and G.T. Golm Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis Int J Clin Pract 64 2010 984 990
8. S.L. Anderson, and J.M. Trujillo Association of pancreatitis with glucagon-like peptide-1 agonist use Ann Pharmacother 44 2010 904 909
9. J.A. Koehler, L.L. Baggio, and B.J. Lamont Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice Diabetes 58 2009 2148 2161
10. Scientific discussion http://www.ema.europa.eu/docs Accessed April 26, 2011
11. J.S. Nachnani, D.G. Bulchandani, and A. Nookala Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas Diabetologia 53 2010 153 159
12. Arzneimittelkommission der Deutschen rzteschaft (Drug Commission of the German Medical Association) "Aus der UAW-Datenbank": Pankreaskarzinome im Zusammenhang mit Exenatid (Byetta®) Dtsch Arztebl 108 2011 A1080
13. S. Yachida, S. Jones, and I. Bozic Distant metastasis occurs late during the genetic evolution of pancreatic cancer Nature 467 2010 1114 1117
14. A.V. Matveyenko, S. Dry, and H.I. Cox Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin Diabetes 58 2009 1604 1615
15. P.L. Brubaker, and D.J. Drucker Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system Endocrinology 145 2004 2653 2659 (Pubitemid 38686211)
16. Scientific discussion http://www.ema.europa.eu/docs Accessed May 03, 2011
17. Victoza ® (liraglutide injection): Human Relevance of Rodent Thyroid C-cell Tumors http://www.fda.gov Accessed April 26, 2011
18. L. Hazell, and S.A. Shakir Under-reporting of adverse drug reactions: a systematic review Drug Saf 29 2006 385 396
19. D. Cohen Rosiglitazone: what went wrong? BMJ 6 2010 530 534 341
20. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471 (Pubitemid 46919772)
21. P.D. Home, S.J. Pocock, and H. Beck-Nielsen JJ; RECORD Study Team Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 373 2009 2125 2135